Objective: To identify the genetic basis of a family segregating episodic ataxia, infantile seizures, and heterogeneous epilepsies and to study the phenotypic spectrum of KCNA2 mutations.
genes including the potassium channel gene KCNA1 (OMIM: 160120) 7 and the calcium channel gene CACNA1A (OMIM: 601011). 8 Here, we expand the repertoire of genes for the EAs, particularly when associated with seizures.
Voltage-gated potassium (K 1 ) channels are encoded by 40 genes representing 12 protein subfamilies K v 12K v 12. 9 The K v 1 or shaker subfamily channels comprise heterotetramers or homotetramers of a-subunits that have 6 a-helical transmembrane domains (S1-S6). 10 The transmembrane domains form the voltage sensor (S1-S4) and the surface of the channel pore (S5 and S6). The K v 1 family channels are broadly expressed; however, individual isoforms are expressed in different combinations in different tissues. 11 K v 1.1, K v 1.2, and K v 1.4 are the most highly expressed subunits in the CNS. 11 KCNA2 encodes an a-subunit of the K v 1.2 channel. Mice null for Kcna2 have a shortened lifespan, seizures, and ataxia. 12 Using whole genome sequencing, we discovered an in-frame deletion in KCNA2 (CCDS_827.1: c.765_773del;p.255_257del) that segregated with a dominant epilepsy-EA syndrome with marked variation in severity within the family. , was initially referred with a history of autosomal dominant infantile-onset seizures and a movement disorder. 13 Since publication, 3 new affected children have been born and the phenotype of the proband has evolved, extending the spectrum of their familial syndrome to include focal epilepsy and EE. Two individuals (WF-I-1, WF-III-6) underwent whole genome sequencing.
KCNA2 was then sequenced in 35 patients with EA alone (1), EA and epilepsy (1) , other paroxysmal movement disorders with seizures (n 5 7) and without (n 5 7), epilepsy and chronic ataxia (n 5 2), and infantile seizures alone (n 5 17). Participants were recruited from epilepsy clinics, private practices, and by referral to our epilepsy and related conditions genetics research program. Detailed phenotypic information was obtained from participants and family members using a validated seizure questionnaire. 14 All medical records, EEG, and neuroimaging data were obtained where available.
Standard protocol approvals, registrations, and patient consents. Informed written consent was obtained from participants or their parents in the case of minors. The study was approved by the Austin Health Human Research Ethics Committee, Australia.
Whole genome and whole exome sequencing. Whole genome sequencing (150 bp, paired end) was performed using Family with an autosomal dominant KCNA2 mutation associated with epilepsy and episodic ataxia (A) WF family pedigree. The KCNA2 mutation (*) segregates with affected status in all individuals. The SCN2A variant (#) is inherited from the unaffected mother. (B) A 9-base pair heterozygous deletion identified in WF-I-1 and WF-III-6. Alignment of whole genome sequencing reads against hg19 genome as seen in the integrative genome viewer. 40 The translation of the wild-type and mutant alleles is indicated with single letter amino acid codes below the alignment.
an Illumina (San Diego, CA) X-10 platform (Kinghorn Centre for Clinical Genomics, Sydney, Australia). Whole exome sequencing (100 bp, paired-end) was performed by the Australian Genomics Research Facility using sequence capture targets from the SureSelectXT Exome enrichment kit V5 (Agilent Technologies, Santa Clara, CA). Reads were mapped to the human genome build (hg19) with BWA-MEM using default options. 15 Alignments were refined with local realignment around indels and variants called and refined using the genome analysis toolkit (GATK) v3.2-2. 16 Variants that passed GATK quality filters and were shared between affected individuals were identified using vcftools. Systematic variant calling errors and common variants were removed using vcf contrast against a set of variants found in at least 3 of 8 other unrelated genomes called at the same time. The remaining variants were annotated with ANNOVAR prior to further filtering. 17 Oocytes (stage V-VI) were isolated from Xenopus laevis as described previously. 20 Oocytes were injected with 50 ng of each cRNA using a Roboinject (Multichannel Systems, Reutlingen, Germany). After 2 days of incubation, 2-electrode voltage clamp recording was performed on a Roboocyte2 (Multichannel Systems). Electrodes contained 1.5 M KC 2 H 3 O 2 and 0.5 M KCl and oocytes were held at 280 mV. Experiments were performed in ND96, which contained 96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , and 5 mM HEPES, pH 7.5. Current was recorded using P/4 correction with a series of 600-ms steps from 260 to 140 mV in 10-mV increments with a 2-second interval between steps. Data were recorded at 2 kHz and temperature maintained at 22 8 C-24 8 C.
Modeling of protein structure. Wild-type and mutant KCNA2 sequences were submitted to the I-TASSER server 21 and predictions of protein structure made against existing models using default measures. Images were generated from predicted structures that had the highest C-score with Swiss PDB viewer v4.04. 22 Calculation of root mean square (RMS) differences between mutant and wild-type carbon alpha chains was performed by selecting the most displaced amino acids in the region surrounding the deletion in both the mutant and wild-type proteins and using the "Calculate RMS." option in Swiss PDB viewer v4.04. 22 RESULTS Phenotypic analysis. Family WF. The family comprised 7 affected individuals over 3 generations (family WF) 13 ( figure 1A and table 1 ). All 7 individuals had epilepsy and 5 had EA. The family included 3 affected adults with EA including 2 with GGE. Six of the 7 individuals had infantile-onset seizures, 3 evolving to GGE alone, GGE and focal epilepsy in 1, and a severe EE (table 1) .
Infantile onset of seizures occurred at a median of 7 months (6-15 months) with clusters of generalized tonic-clonic seizures (GTCS). The 54-year-old father (WF-II-3) had rare GTCS thereafter until 44 years. The cousin (WF-III-7) was seizure-free from 9 months until 8 years, when occipital seizures developed. Absence seizures associated with 3-Hz generalized spike-wave were recorded at 9 years with rare GTCS thereafter. The proband WF-III-4 had GTCS until 5 years, with 2 later GTCS at 19 and 20 years associated with medication noncompliance. WF-II-4 had 4 GTCS with a single afebrile convulsion at 15 months and 3 between 19 and 24 years. Two individuals had childhood absence epilepsy, with the proband evolving to juvenile myoclonic epilepsy. All 4 individuals with GGE had generalized spike-wave activity with photic sensitivity; the cousin (WF-III-7) also had occipital sharp waves. The proband's brother (WF-III-5) had focal epilepsy beginning at age 13 years with a perceptual aura of the environment "going fast around him." He had 2 tonic-clonic seizures at 16 and 19 years. The proband, her brother, and her cousin all had delayed speech development, with first words between 18 months and 3 years. The siblings WF-III-4 and WF-III-5 had low average intellect in late childhood and their cousin WF-III-7 had mild intellectual disability (full-scale IQ 69) and high functioning autism. Development in the father, aunt, and grandmother was normal.
Five individuals had EA beginning at mean 8 years (median 9 years, range 5-12 years). It was characterized by loss of coordination in the lower limbs, often associated with dysarthria.
Individuals reported a vague warning before onset of an episode, retained awareness during the event, and dysarthria often preceding and persisting beyond involvement of limbs. No myokymia or nystagmus was observed. Episodes often occurred in clusters and varied in duration from brief attacks lasting 15 seconds to prolonged episodes lasting up to 12 hours. The events were triggered by exercise, fatigue, illness, menstruation, startle, stress, and sudden movement. Acetazolamide was effective in reducing episodes in 2 individuals.
Individual WF-III-6, aged 14 years, has a severe epileptic encephalopathy. He had normal development until tonic-clonic seizures began at 7 months, and frequent photic induced absence seizures were observed by 13 months. Myoclonus was present at 18 months, with multifocal myoclonus evident by 6 years. He had frequent nonconvulsive status epilepticus requiring admission and routinely had 80 absence seizures per day. He was refractory to multiple antiepileptic medications. He had severe intellectual disability and a crouch gait. Generalized spike-wave and polyspike-wave with photic sensitivity was seen on EEG.
Proband B. Proband B, with a de novo KCNA2 mutation (see below), had onset of tonic seizures with pallor at 12 months. Seizures were initially triggered by minor head injuries and later occurred with infection, fever, or on awakening. Absence seizures commenced at 5 years following withdrawal of lamotrigine. Erratic myoclonic tremor began at 2 years following commencement of valproate but did not worsen with lamotrigine; this was exacerbated by illness, fatigue, stress, and on awakening for 1.5 hours (videos). Her gait was mildly ataxic; paroxysmal ataxia was not observed. There was no family history of tremor and a bilineal distant family history of epilepsy. Her development was initially normal and slowed with seizure onset. Neuropsychological assessment at 9 years showed significant verbal (average range)-nonverbal (extremely low range) discrepancy in the setting of an overall borderline IQ; this was not wholly explained by her difficulties with movement and tremor. EEG was normal at 14 months. At 2, 4, and 7 years, background activity was slow. Frequent long runs of bisynchronous occipital spike-wave were seen, particularly with eye closure and drowsiness but not with photic stimulation. Generalized spike-wave and rare focal discharges were also seen.
Molecular analysis. Whole genome sequence reads from the grandmother WF-I-1 and her grandson WF-III-6 were mapped to the human genome hg19 and achieved a median depth of 29 reads with minimum mapping and base quality Phred scores of 20. There were 1,565,560 variants shared between genomes. After filtering variants that were unlikely to be disease-causing based on population frequency and prediction of functional effects, we found 4 candidate genes (table e-2). Of these, a deletion in KCNA2 (CCDS_827.1: c.765_773del; p.255_257del) ( figure 1B) was favored because both knockout and ENU-induced Kcna2 mutant mice exhibit seizures and ataxia 12, 23 and de novo KCNA2 mutations cause EE. [1] [2] [3] [4] [5] The remaining 3 genes in which variants were found (EGR4, MET, RNF19B) have not been implicated in epilepsy or ataxia (table e-2). The KCNA2 variant segregated with all affected individuals ( figure 1B) .
We performed whole exome sequencing of both parents of WF-III-6 and sought de novo, X-linked, potentially autosomal recessive, and maternally inherited variants in known or predicted epilepsy genes that might account for the increased severity of the phenotype in this individual (WF-III-6) compared to other family members. From these analyses, we identified 4 X-linked variants, 2 genes with compound heterozygous missense variants and 3 de novo variants, all of unknown effect (table e-3). We found only one variant that was inherited from the unaffected mother (WF-II-3) of WF-III-6 in a gene previously implicated in EE; SCN2A (NM_001040143: c.82C.T; p.Arg28Cys; rs200884216). It was also present in his sister WF-III-4 but not in other affected family members. This variant was predicted to be damaging by several algorithms, is found in the general population at low frequency (ExAC 2.21 3 10 24 , table e-3), and could potentially modify the phenotype in WF-III-6.
We screened the KCNA2 open reading frame and identified a recurrent de novo mutation (c.890G.A; p.Arg297Gln) in 1/35 individuals (proband B) in our cohort. 1,2 p.Arg297Gln neutralizes the second arginine in the voltage sensor in K v 1.2. Voltage clamp assays demonstrated a 9-fold increase in current amplitude and a shift of voltage-dependent activation by 240 mV compared with wild-type, also observed for a mixture of WT and mutant channels, thus consistent with a dominant, strong gain of function. 2 To test the effect of the familial KCNA2 c.765_773del mutation on channel function, we expressed the mutant, wild-type, and a combination of both in Xenopus laevis oocytes. Oocytes expressing only wild-type KCNA2 showed voltage-dependent activation with a peak current of 1.82 6 0.24 mA at 140 mV. In contrast, expression of KCNA2 c.765_773del yielded significantly lower currents that peaked at 0.21 6 0.02 mA at 140 mV. We injected equivalent amounts of wild-type and KCNA2 c.765_773del cRNAs and found clear evidence of dominant negative effect as peak current was 0.28 6 0.08 mA at 140 mV compared to wildtype alone ( figure 2, A and B) . The KCNA2 c.765_773del;p.255_257del mutation deletes residues that are identical in all mammalian, avian, amphibian and fish species examined ( figure 3A ). KCNA2 p.Arg297 is invariable in mammals, fish, amphibians, and insects and is also highly conserved in the voltage-sensing domains of other ion channels. 2, 24 We used molecular modeling to predict the effect of the p.255_257del mutation on the structure of KCNA2 (Protein Databank ID: 2R9R). These analyses predicted an increase in the a-helical content of S3, removing a turn in that helix that is usually juxtaposed with the cytoplasmic side of the plasma membrane ( figure 3B) . Analysis of the model 3D structure revealed a local 3.03 Å root mean square difference in the position of the mutant compared to the wild-type carbon a-chain backbone ( figure 3C ). The model also predicts altered positioning of critical residues Arg294 (R1) and Arg309 (R6) on the S4 helix of the voltage-sensing domain ( figure 3C ). KCNA2 shows remarkable coexpression with other genes implicated in EA (KCNA1, CACNA1A, CACNB4, SLC1A3; figure e-1). 11 DISCUSSION Seven mutations in KCNA2 have been identified in 11 unrelated individuals with EE (figure e-2). [1] [2] [3] [4] [5] Here, we report the first autosomal dominant KCNA2 disorder with a predominant phenotype of infantile-onset seizures with later GGE or focal epilepsy in the setting of normal intellect. We implicate KCNA2 in EA for the first time. We also report a recurrent de novo mutation, highlighting a mutational hotspot (figure e-2). 1, 2 Family WF considerably expands the phenotypic spectrum of KCNA2 diseases to include mild wellcontrolled epilepsies and EA. All but one affected individual had infantile-onset seizures leading us initially to consider infantile convulsions choreoathetosis syndrome (ICCA), 25 although the movement disorder, EA, is clinically distinct from paroxysmal kinesigenic choreoathetosis. Their later evolution to GGE and focal epilepsy is also unusual for ICCA. PRRT2 sequencing was negative in WF-III-4. 25 Many types of EA are recognized. EA1 is associated KCNA1 mutation and focal epilepsy, 26 while EA2 due to CACNA1A mutations is associated with generalized epilepsy. 27 Mutational analysis of these genes was negative (CACNA1A in WF-II-4, KCNA1 in WF-II-3). Our findings strengthen the phenotypic overlap observed between KCNA1 and KCNA2; the corresponding mutation in K v 1.1 p.Ile262Thr caused EA1 with distal weakness, while K v 1.2 p.Ile263Thr caused EE. 2, 28 We show that KCNA2 is a cause of EA; further EA cohorts should be tested for KCNA2 mutations.
The KCNA2 p.255_257del mutation was fully penetrant in the family although there was a wide spectrum of phenotypic severity. As the boy WF-III-6 had a severe EE, we explored whether a second hit mutation could account for his far more severe phenotype by performing whole exome studies on his parents. We identified an SCN2A variant (NM_001040143: c.82C.T; p.Arg28Cys; rs200884216) that was predicted to be damaging, inherited from his unaffected mother and also present in his sister WF-III-4. Computer modeling indicates that multiple small changes in ion channel properties can lead to large changes in network excitability 29 and firing patterns of individual neurons. 30 Identifying and predicting which factors modify phenotypes remains a challenge for the future.
The EE in WF-III-6 and Proband B are congruent with 9 previous KCNA2 mutation cases but differ markedly in severity. [1] [2] [3] Proband B shared the constant myoclonus (videos) reported in other cases, together with absence seizures and ataxia. WF-III-6 had severe intellectual disability, about 100 absences daily, and frequent nonconvulsive status epilepticus. 1 However, it has to be considered whether WF-III-6's phenotype has been modified by the SCN2A variant.
The p.255_257del mutation is located in the third transmembrane domain S3, near the S2-S3 linker region. 31 The deletion occurs adjacent to Asp259, which is a critical residue in the voltage-sensing domain. 31 The predicted altered structure of the p.255_257del mutant protein could reduce protein stability. The mutation may also interfere with the function of the voltage-sensing domain, given the proximity of the mutation to Asp259 and the predicted repositioning of Arg294 and Arg309, which are conserved residues (R1 and R6) in most ion channels. 24 The dominant negative effect we measured by voltage clamp assay suggests that the KCNA2 p.255_257del mutant can be incorporated into K v 1.2 channels. In tissues where there is a mix of K v 1 isoforms, the mutant KCNA2 proteins could interact with other a-subunits expressed from shaker subfamily genes, potentially blocking their function. 32, 33 KCNA2 diseases add to the emerging phenotypic spectrum characteristic of many ion channel disorders. For example, benign familial neonatal epilepsy is associated with mutations in KCNQ2 and KCNQ3, in which autosomal dominant inheritance is usual and the outcome is excellent. 34, 35 In contrast, KCNQ2 encephalopathy is associated with more refractory epilepsy, cerebral palsy, and a devastating prognosis 36 ; de novo mutations are usual. Similarly, sodium channel diseases (e.g., SCN1A, SCN2A) cause both selflimited, pharmacoresponsive epilepsies in the setting of normal intellect and EEs. Although some phenotype-genotype correlations have been reported for these genetic diseases, often the phenotypic outcome associated with a specific variant is unpredictable.
There is increasing recognition of the overlap between the epilepsies and movement disorders and is seen frequently in the EEs. For example, KCNA2 encephalopathy is associated with ataxia and dystonia, 1,2 SCN2A encephalopathy with dystonia, choreoathetosis, 37 and EA, 38 and SCN8A encephalopathy with choreoathetosis, dystonia, and ataxia. 39 The diversity of movement disorders for each genetic encephalopathy expands as further cases are identified. These findings illustrate the critical importance of understanding the phenotypic diversity of a genetic disorder.
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